Recent News

• 04.23.2025 - Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
• 04.23.2025 - Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases
• 04.15.2025 - Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
• 04.15.2025 - Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
• 04.07.2025 - Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 04.07.2025 - Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 01.28.2025 - Brandon Folkes, CFA
• 01.28.2025 - Brandon Folkes, CFA
• 01.22.2025 - Kemp Dolliver, CFA
• 01.22.2025 - Kemp Dolliver, CFA

Recent Filings

• 04.22.2025 - 8-K Current report
• 04.17.2025 - 8-K Current report
• 04.07.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
• 01.10.2025 - 8-K Current report
• 12.09.2024 - 4 Statement of changes in beneficial ownership of securities